Buscar
Congreso SOLACI
HomeInternational CongressesAHA 2012.

AHA 2012.

Ver Categoría
Day 3

SWISS AMI: Stem cells infusion after primary angioplasty

The trial enrolled 200 patients post AMI treated with successful PCI, with LVEF ≤45% randomized to placebo,...
solaci -
Ver más
Day 3

PILOT trial: Pilot study of two levels of hypothermia in comatose survivors after out-of-hospital cardiorespiratory arrest.

Hypothermia is neuroprotective, because it reduces brain oxygen consumption in 6%, suppresses chemical reactions associated to reperfusion,...
solaci -
Ver más
Day 3

ALCADIA: An intra-myocardial injection of autologous cardiac derived stem cells improves ventricular function in patients with ischemic cardiomyopathy.

This is an open trial that included 7 patients with ischemic cardiomyopathy and reduced the ejection fraction...
solaci -
Ver más
Day 3

SCIPIO trial: Intracoronary infusion of autologous cardiac stem cells improve ventricular function.

This is the first trial that used autologous cardiac stem cells for the treatment of ischemic cardiomyopathy....
solaci -
Ver más
Day 3

POSEIDON: Transendocardial infusion of autologous vs. allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy.

Safety and efficacy of autologous vs. allogeneic mesenchymal stem cells had not yet been compared. This trial...
solaci -
Ver más
Day 3

TIME: Use and duration of bone marrow derived stem cells infusion for the treatment of post infarction ventricular dysfunction.

This study randomized 120 patients with acute myocardial infarction after successful primary angioplasty with a residual ejection...
solaci -
Ver más
Day 2

PHS II Trial: Use of multivitamins in the prevention of cardiovascular disease in men.

Observational studies have shown contradicting results on the use of multivitamins. PHS II is the only randomized...
solaci -
Ver más
Day 2

GAUSS trial: Antibodies for the treatment of hypercholesterolemia in patients with statin intolerance.

Statins are the most effective treatment to reduce LDL levels and cardiovascular risk, 10-20% of patients are...
solaci -
Ver más

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

Dr. Omar Tupayachi - 0
While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Dr. Andrés Rodríguez - 0
Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Dr. Omar Tupayachi - 0
Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Noticias Institucionales

Check out the best images of the El Salvador 2024 Sessions

solaci - 0
Review the highlights of the XLIX SOLACI Regional Sessions held at the Intercontinental Hotel in San Salvador, El Salvador between November 7 and 8,...

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

solaci - 0
Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad